{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:02:42Z","timestamp":1790906562967,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundaci\u00f3n SENEFRO"},{"DOI":"10.13039\/100015883","name":"Sociedad Espa\u00f1ola de Nefrolog\u00eda","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015883","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III RICORS program","award":["RICORS2040"],"award-info":[{"award-number":["RICORS2040"]}]},{"name":"Instituto de Salud Carlos III RICORS program","award":["RD21\/0005\/0022"],"award-info":[{"award-number":["RD21\/0005\/0022"]}]},{"name":"European Union\u2014NextGenerationEU"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The nephrotoxicity of chimeric antigen receptor T-cell (CAR-T) therapy has been reported, yet data on urinary abnormalities remain limited. This study aimed to characterize proteinuria, acute kidney injury (AKI), and associated electrolyte disorders in patients treated with CAR-T therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective analysis was conducted on 63 patients treated with CAR-T therapy between June 2020 and December 2023. Blood tests were collected daily during hospitalization and a first morning urine void was collected on day of infusion (D0), +7 (D7), and +14 (D14).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period, 12 patients (19%) developed AKI. The median urine protein-to-creatinine ratio (uPCR) increased significantly from 0.17 g\/g on D0 to 0.39 g\/g on D7, returning to baseline levels at D14. Proteinuria &amp;gt;0.5 g\/g was detected in 37% of patients at D7. Patients with AKI before D7 had higher proteinuria than patients without AKI or AKI after D7. Proteinuria was associated with higher levels of lactate dehydrogenase (LDH), interleukin-6 levels and cytokine release syndrome (CRS) grade $\\ge$3. Patients with higher proteinuria had more progression of hematological disease and increased mortality in the first year. Furthermore, 60 patients (95%) experienced at least one electrolyte disorder, hypophosphatemia being the most frequent. Higher proteinuria was associated with lower levels of phosphorus, potassium, and sodium.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CAR-T therapy is associated with transient renal adverse effects, including proteinuria, AKI, and electrolyte disorders. Systemic inflammation-mediated tubular injury contributed to these adverse effects. These findings enhance our understanding of CAR-T therapy nephrotoxicity. Proteinuria levels at D0 may be associated with disease progression and mortality within the first year.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfaf270","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T11:30:56Z","timestamp":1756207856000},"source":"Crossref","is-referenced-by-count":5,"title":["Prospective evaluation of CAR-T cell therapy-related proteinuria and kidney dysfunction"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1812-4098","authenticated-orcid":false,"given":"Francesc","family":"Moncho-Franc\u00e9s","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Valencia, INCLIVA Biomedical Research Institute Nephrology Department, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Hernani","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Valencia, INCLIVA Biomedical Research Institute Hematology Department, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Juan-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Valencia, INCLIVA Biomedical Research Institute Nephrology Department, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Benzaqu\u00e9n","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Valencia, INCLIVA Biomedical Research Institute Hematology Department, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Sol\u00eds-Salguero","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Valencia, INCLIVA Biomedical Research Institute Nephrology Department, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Valencia, INCLIVA Biomedical Research Institute Hematology Department, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-7474","authenticated-orcid":false,"given":"Juan F","family":"Navarro-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Nuestra Se\u00f1ora de Candelaria Research Unit and Nephrology Department, , Santa Cruz de Tenerife ,","place":["Spain"]},{"name":"Institute of Biomedical Technologies, Universidad de La Laguna , La Laguna, Santa Cruz de Tenerife ,","place":["Spain"]},{"name":"Faculty of Health Sciences, Universidad Fernando Pessoa Canarias , Las Palmas de Gran Canaria ,","place":["Spain"]},{"name":"Instituto de Salud Carlos III RICORS2040-RENAL (RD24\/0004\/0022), , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-2562","authenticated-orcid":false,"given":"Jose Luis","family":"Pi\u00f1ana","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Valencia, INCLIVA Biomedical Research Institute Hematology Department, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Valencia, INCLIVA Biomedical Research Institute Hematology Department, , Valencia ,","place":["Spain"]},{"name":"Faculty of Medicine, Universitat de Val\u00e8ncia Department of Medicine, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Terol Caster\u00e1","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Valencia, INCLIVA Biomedical Research Institute Hematology Department, , Valencia ,","place":["Spain"]},{"name":"Faculty of Medicine, Universitat de Val\u00e8ncia Department of Medicine, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Valencia, INCLIVA Biomedical Research Institute Hematology Department, , Valencia ,","place":["Spain"]},{"name":"Faculty of Medicine, Universitat de Val\u00e8ncia Department of Medicine, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1134-9051","authenticated-orcid":false,"given":"Jose L","family":"G\u00f3rriz","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Valencia, INCLIVA Biomedical Research Institute Nephrology Department, , Valencia ,","place":["Spain"]},{"name":"Instituto de Salud Carlos III RICORS2040-RENAL (RD24\/0004\/0022), , Madrid ,","place":["Spain"]},{"name":"Faculty of Medicine, Universitat de Val\u00e8ncia Department of Medicine, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Torregrosa","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Valencia, INCLIVA Biomedical Research Institute Nephrology Department, , Valencia ,","place":["Spain"]},{"name":"Faculty of Medicine, Universitat de Val\u00e8ncia Department of Medicine, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"2025100605121928600_bib1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100605121928600_bib2","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"2025100605121928600_bib3","doi-asserted-by":"publisher","first-page":"e3484","DOI":"10.1002\/jgm.3484","article-title":"Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment","volume":"25","author":"Adabi","year":"2023","journal-title":"J Gene Med"},{"key":"2025100605121928600_bib4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"2025100605121928600_bib5","doi-asserted-by":"publisher","first-page":"102479","DOI":"10.1016\/j.ctrv.2022.102479","article-title":"Toxicities following CAR-T therapy for hematological malignancies","volume":"111","author":"Hernani","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2025100605121928600_bib6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"2025100605121928600_bib7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025100605121928600_bib8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","article-title":"Notice","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2025100605121928600_bib9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"2025100605121928600_bib10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.clinph.2024.04.014","article-title":"EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome","volume":"163","author":"Hernani","year":"2024","journal-title":"Clin Neurophysiol Off J Int Fed Clin Neurophysiol"},{"key":"2025100605121928600_bib11","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025100605121928600_bib12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12885-022-09915-4","article-title":"The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma","volume":"22","author":"Park","year":"2022","journal-title":"BMC Cancer"},{"key":"2025100605121928600_bib13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"2025100605121928600_bib14","doi-asserted-by":"publisher","first-page":"sfae123","DOI":"10.1093\/ckj\/sfae123","article-title":"Acute kidney injury after CAR-T cell therapy: exploring clinical patterns, management, and outcomes","volume":"17","author":"Vincendeau","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025100605121928600_bib15","doi-asserted-by":"crossref","first-page":"sfae027","DOI":"10.1093\/ckj\/sfae027","article-title":"Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies","volume":"17","author":"Le\u00f3n-Rom\u00e1n","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025100605121928600_bib16","doi-asserted-by":"publisher","first-page":"sfae359","DOI":"10.1093\/ckj\/sfae359","article-title":"Acute kidney injury following CAR-T cell therapy: a nephrologist's perspective","volume":"18","author":"Kanbay","year":"2025","journal-title":"Clin Kidney J"},{"key":"2025100605121928600_bib17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/ckj\/sfaa164","article-title":"The complex interplay between kidney injury and inflammation","volume":"14","author":"McWilliam","year":"2021","journal-title":"Clin Kidney J"},{"key":"2025100605121928600_bib18","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.mayocp.2022.05.018","article-title":"Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy","volume":"97","author":"Farooqui","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2025100605121928600_bib19","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1158\/2326-6066.CIR-22-0418","article-title":"Hypophosphatemia due to increased effector cell metabolic activity is associated with neurotoxicity symptoms in CD19-targeted CAR T-cell therapy","volume":"10","author":"Tang","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025100605121928600_bib20","doi-asserted-by":"publisher","first-page":"F517","DOI":"10.1152\/ajprenal.00291.2005","article-title":"Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury","volume":"290","author":"Vaidya","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025100605121928600_bib21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1053\/j.ajkd.2008.07.008","article-title":"NGAL in acute kidney injury: from serendipity to utility","volume":"52","author":"Devarajan","year":"2008","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf270\/64143581\/sfaf270.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/10\/sfaf270\/64143581\/sfaf270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/10\/sfaf270\/64143581\/sfaf270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:12:22Z","timestamp":1759741942000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf270\/8242165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf270","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,27]]},"article-number":"sfaf270"}}